Curaleaf (OTCMKTS:CURLF) Sets New 1-Year High – Still a Buy?

Curaleaf Holdings, Inc. (OTCMKTS:CURLF)’s stock price reached a new 52-week high during trading on Thursday . The company traded as high as $5.01 and last traded at $4.70, with a volume of 5314793 shares trading hands. The stock had previously closed at $4.5330.

Trending Headlines about Curaleaf

Here are the key news stories impacting Curaleaf this week:

• Positive Sentiment: Federal rescheduling announced by the administration could materially improve the industry outlook — easing tax burdens, opening banking and institutional investment, and unlocking research and M&A optionality; this sector tailwind supports higher multiples for multistate operators like Curaleaf. Trump Orders Marijuana Reclassification: What It Means for the Sector
• Positive Sentiment: Curaleaf publicly applauded the rescheduling action, signaling management expects tangible benefits (research, banking, tax) that could improve cash flow, reduce regulatory friction and support future uplisting or institutional demand. Curaleaf Celebrates President Trump’s Landmark Rescheduling of Cannabis Under Controlled Substances Act
• Neutral Sentiment: Analyst and trade commentary (MarketBeat) highlight Curaleaf’s scale and positioning to benefit from rescheduling and industry re‑rating, but note upside may be volatile and headline‑driven while regulatory details are implemented. Cannabis Stocks Up for Reversal: Pipedreams or Opportunity?
• Neutral Sentiment: Retail and small‑cap cannabis coverage (MarijuanaStocks) flags short‑term volatility and speculative interest in penny/OTC cannabis names as traders front‑run policy moves — a reminder that sentiment can overshoot fundamentals. Best U.S. Cannabis Penny Stocks to Trade Now With Rescheduling Momentum
• Negative Sentiment: Curaleaf announced termination of its equity purchase agreement to acquire The Cannabist Company’s Virginia assets — this removes near‑term incremental revenue and retail footprint expansion, and may slow inorganic growth expectations; investors often view failed deals as a negative signal for execution or pipeline. Curaleaf Announces Termination of Equity Purchase Agreement with The Cannabist Company
• Negative Sentiment: Local reporting notes Curaleaf formally ended its agreement to buy Cannabist Virginia assets — the market may view this as reducing M&A-driven growth visibility in key adult‑use states like Virginia. Curaleaf ends agreement to buy Cannabist Virginia assets

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Canaccord Genuity Group raised Curaleaf to a “strong-buy” rating in a research report on Thursday, October 9th. Atb Cap Markets raised shares of Curaleaf from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 2nd. Finally, ATB Capital upgraded shares of Curaleaf to an “outperform” rating in a research report on Tuesday, December 2nd. Two research analysts have rated the stock with a Strong Buy rating and one has given a Buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Strong Buy”.

Curaleaf Stock Down 5.5%

The company has a market capitalization of $2.05 billion, a PE ratio of -9.43 and a beta of 0.77. The company has a current ratio of 1.47, a quick ratio of 0.71 and a debt-to-equity ratio of 0.96. The business has a fifty day moving average of $2.76 and a 200 day moving average of $2.22.

Curaleaf (OTCMKTS:CURLF) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. Curaleaf had a negative net margin of 19.50% and a negative return on equity of 15.57%. Equities research analysts anticipate that Curaleaf Holdings, Inc. will post -0.25 EPS for the current year.

About Curaleaf

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.